错配修复完整结直肠癌通过内在抑制程序逃逸免疫监视
该研究构建了表达相同水平特定抗原的MSI与MSS结直肠癌细胞模型,发现尽管抗原提呈相当,MSS肿瘤仍表现出T细胞活化受损、细胞毒性降低和杀伤抵抗。MSS肿瘤分泌组通过损害免疫突触形成抑制免疫反应,甚至影响免疫原性MSI细胞;表面蛋白组学鉴定出糖基化依赖的改变 impair 免疫识别,提示MSS结直肠癌通过不依赖抗原性的分泌组驱动机制逃逸免疫攻击。
要点
- MSS结直肠癌即使抗原提呈与MSI相当,仍抵抗T细胞杀伤。
- MSS肿瘤分泌组可抑制免疫突触形成,介导抗原非依赖性免疫逃逸。
- 糖基化依赖的表面蛋白改变损害免疫识别,或为可靶向通路。
核心结论
- MSS结直肠癌通过内在分泌组驱动的糖基化依赖机制逃逸T细胞攻击,独立于抗原性。
研究设计与样本
- 工程化MSI和MSS结直肠癌细胞表达相同水平的特定抗原,该抗原可被TCR工程化T细胞识别。
主要发现
- 尽管抗原提呈相当,MSS肿瘤表现出T细胞活化受损、细胞毒性降低和杀伤抵抗。
- MSS肿瘤分泌组通过损害免疫突触形成抑制免疫反应,甚至影响免疫原性MSI细胞。
- 质谱表面蛋白组学鉴定出糖基化依赖的改变,损害免疫识别。
临床怎么用
- 靶向糖基化相关的抑制通路可能恢复T细胞反应性并改善MSS结直肠癌的免疫治疗疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Although microsatellite-instable (MSI) colorectal cancers, reflecting mismatch repair (MMR) deficiency, often respond to immune checkpoint inhibitors, microsatellite-stable (MSS) tumors remain largely resistant. This disparity is typically attributed to differences in neoantigen load. However, whether antigen-independent mechanisms contribute to immune evasion in MSS colorectal cancer remains unclear. To address this, we engineered a model in which MSI and MSS colorectal cancer cells express identical levels of a defined antigen recognized by T-cell receptor-engineered T cells. Despite equivalent antigen presentation, MSS tumors exhibited impaired T-cell activation, reduced cytotoxicity, and resistance to killing. We linked this immune evasion to the MSS tumor secretome, which suppressed immune responses even in immunogenic MSI cells by impairing immune synapse formation. Surfaceome profiling by mass spectrometry identified glycosylation-dependent alterations that impair immune recognition. Our findings demonstrate that MSS colorectal cancer evades immune attack via intrinsic secretome-driven mechanisms, independent of antigenicity. Targeting glycosylation-linked suppressive pathways may restore T-cell responsiveness and improve immunotherapy efficacy in MSS colorectal cancer. SIGNIFICANCE: This study reveals that MMR-proficient colorectal cancers resist T-cell attack not only due to low neoantigen load but also through glycosylation-dependent, secretome-mediated immunosuppression. These findings uncover a previously unrecognized immune evasion mechanism and identify actionable pathways to restore immunotherapy responsiveness in resistant colorectal tumors.
引用
- Cattaneo CM, Scardellato S, Mauri G, et al. Mismatch Repair-Proficient Colorectal Cancer Can Evade Immune Surveillance through an Intrinsic Suppressive Program. Cancer Discov. 2026. PMID: 42126206. doi:10.1158/2159-8290.CD-26-0542
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。